Myriad Genetics Receives Additional Reimbursement for myChoice Diagnostic System in Japan - Seite 2
“The use of genetic testing and precision medicine is increasingly important when it comes to guiding treatment for women with advanced ovarian cancer,” said Nicole Lambert, president of Myriad Genetic Laboratories. “The approval and now additional reimbursement of the myChoice test will empower healthcare professionals in Japan to better identify and treat patients who may respond to targeted therapy. Our work with AstraZeneca is another example of how strong collaboration among industry leaders can benefit patients and providers.”
Myriad has been working with AstraZeneca since 2007 on the development of companion diagnostics for Lynparza. Lynparza is a trademark of AstraZeneca. Lynparza is jointly developed and commercialized by AstraZeneca and Merck (known as MSD Inc. outside the United States and Canada). Additionally, Myriad has partnered with SRL Inc., a subsidiary of H.U. Group Holdings, Inc. to expand the commercialization of the myChoice Diagnostic System in Japan.
About the myChoice Diagnostic System
Myriad myChoice is the most comprehensive homologous recombination deficiency (HRD) test, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded
DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The myChoice test comprises tumor sequencing of the BRCA1 and
BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions). For more information, visit: https://myriad-oncology.com/mychoice-cdx/
About SRL
Since the establishment in 1970, SRL, Inc., a member of the H.U. Group Holdings, Inc., Japan-based leading healthcare group, has been providing comprehensive testing services as the largest
commercial clinical laboratory in Japan. SRL carries out nearly 400,000,000 tests per year, covering a wide range of testing services including general/emergency testing, esoteric/research
testing, companion diagnostics tests, genomic analysis and other tests. For more information, please visit https://www.srl-group.co.jp/english/.
Lesen Sie auch
About Myriad Genetics
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing, empowering individuals with vital genetic insights and enabling
healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease,
assess the risk of disease progression, and guide treatment decisions across medical specialties where genetic testing can significantly improve patient care and lower healthcare costs. For more
information on how Myriad fulfills its purpose, please visit the Company's website: www.myriad.com.